Immunic to Engage in Key October Conferences

Immunic, Inc., a biotechnology firm specializing in oral small molecule therapies for chronic inflammatory and autoimmune diseases, is set to participate in various significant scientific and investor conferences this October. The company's involvement underscores its active role in addressing gastroenterological and neuroimmune conditions.

From October 4-7, Immunic's R&D team will be present at the United European Gastroenterology Week in Berlin, where they will present findings on IMU-856, a potential treatment for celiac disease. On October 5-8, data on IMU-838 will be shared at the International Society of Neuroimmunology Congress in Japan.

Furthermore, on October 9, Immunic's executive leaders will attend Roth’s Healthcare Opportunities Conference in New York. They will later join a virtual discussion on October 23 hosted by H.C. Wainwright. These engagements highlight Immunic's commitment to advancing therapeutic options and maintaining transparency with stakeholders.